Vitex Takes On Baxter: Will Parallel Study Favor Swift Inactine Approval?
This article was originally published in The Gray Sheet
Executive Summary
A parallel arm design for Vitex' Phase III pivotal trial testing the Inactine red blood cell pathogen inactivation system in chronic anemia patients positions Vitex to be the first to market in the U.S., according to the firm